Last reviewed · How we verify
Pf-07284892 (pf-07284892)
At a glance
| Generic name | pf-07284892 |
|---|---|
| Sponsor | Pfizer |
| Drug class | unknown |
| Target | unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP3A4 substrates
Key clinical trials
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- PF-07284892 in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |